Cargando…
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes including RET rearrangements. RET on...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
PAGEPress Publications, Pavia, Italy
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065052/ https://www.ncbi.nlm.nih.gov/pubmed/30093982 http://dx.doi.org/10.4081/oncol.2018.352 |